NCT06624020View on ClinicalTrials.gov

A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

CompletedOBSERVATIONAL
Enrollment

1,128

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Breast Neoplasms
Trial Locations (1)

2000

Pfizer Australia, Sydney

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06624020 - A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia | Biotech Hunter | Biotech Hunter